Abstract A 59 year old man with ischaemic heart disease, developed the clinical and electromyographic changes of the LambertEaton myasthenic syndrome after taking calcium antagonist, diltiazem. The symptoms appeared periodically with a rise and fall in serum level of diltiazem. Extensive search was made for systemic neoplasms and autoimmune diseases without success. Serum antibody to voltage operated calcium channel was not detected. Case report Since the age of 55, the patient had been given diltiazem (90 mg/day) for ischaemic heart disease. At the age of 56, his voice became nasal. Muscle strength of the hands and proximal portions of the four extremities was decreased. The weakness peaked after rest or immediately after waking up in the morning, and the strength tended to improve transiently with brief exercise. Other complaints included dry mouth, decreased sweating, constipation and weight loss. One year after starting the drug, the man noted muscular weakness in the thighs. He had smoked 20 cigarettes per day for 37 years. On admission at the age of 59, there was no abnormality in the movement of the eyes, eyelids, or facial muscles. Sensory examination was normal. Withdrawal of diltiazem was followed by improvement of the nasal voice and muscular weakness. Both symptoms reappeared with diltiazem but again decreased after withdrawal. The serum concentration of diltiazem correlated with the severity of the muscular weakness. Signs of muscular weakness did not change with edrophonium chloride, but were relieved after five days of guanidine (300 mg/day).
Case report
Since the age of 55, the patient had been given diltiazem (90 mg/day) for ischaemic heart disease. At the age of 56, his voice became nasal. Muscle strength of the hands and proximal portions of the four extremities was decreased. The weakness peaked after rest or immediately after waking up in the morning, and the strength tended to improve transiently with brief exercise. Other complaints included dry mouth, decreased sweating, constipation and weight loss. One year after starting the drug, the man noted muscular weakness in the thighs. He had smoked 20 cigarettes per day for 37 years. On admission at the age of 59, there was no abnormality in the movement of the eyes, eyelids, or facial muscles. Sensory examination was normal. Withdrawal of diltiazem was followed by improvement of the nasal voice and muscular weakness. Both symptoms reappeared with diltiazem but again decreased after withdrawal. The serum concentration of diltiazem correlated with the severity of the muscular weakness. Signs of muscular weakness did not change with edrophonium chloride, but were relieved after five days of guanidine (300 mg/day). 
